Geron (NASDAQ:GERN) Stock Rating Upgraded by BidaskClub
Other equities research analysts also recently issued reports about the company. ValuEngine upgraded Geron from a “hold” rating to a “buy” rating in a report on Saturday, August 10th. B. Riley increased their price target on Geron from $3.25 to $4.50 and gave the stock a “buy” rating in a report on Friday, June 28th. Finally, Cantor Fitzgerald assumed coverage on Geron in a report on Thursday. They issued an “overweight” rating and a $4.00 price target on the stock. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $3.46.
Shares of GERN stock opened at $1.41 on Friday. Geron has a 1 year low of $0.95 and a 1 year high of $6.99. The stock’s 50 day simple moving average is $1.29 and its two-hundred day simple moving average is $1.51. The company has a market cap of $261.91 million, a PE ratio of -8.81 and a beta of 2.59.
Hedge funds and other institutional investors have recently modified their holdings of the company. Amalgamated Bank purchased a new stake in shares of Geron in the fourth quarter worth approximately $25,000. Rudd International Inc. purchased a new stake in shares of Geron in the second quarter worth approximately $30,000. Tower Research Capital LLC TRC raised its holdings in shares of Geron by 482.4% in the second quarter. Tower Research Capital LLC TRC now owns 29,801 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 24,684 shares during the period. BNP Paribas Arbitrage SA increased its holdings in Geron by 6,429.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 36,629 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 36,068 shares during the period. Finally, DekaBank Deutsche Girozentrale increased its holdings in Geron by 64.0% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 41,000 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 16,000 shares during the period. Hedge funds and other institutional investors own 31.06% of the company’s stock.
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.